By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Audentes Therapeutics 

101 Montgomery Street
Suite 2650
San Francisco  California  94104  U.S.A.
Phone: 415-638-6556 Fax: n/a


Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.

The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. We take pride in strong, global relationships with the patient, research, and medical communities.

Key Statistics

Ownership: Public

Web Site: Audentes
Employees: n/a
Symbol: BOLD


Company News
Audentes (BOLD) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/9/2017 11:22:37 AM
Audentes (BOLD) Announces Commencement Of LUSTRO, A Clinical Assessment And Phase I/II Run-In Study Of Patients With Crigler-Najjar Syndrome 3/1/2017 7:16:49 AM
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT342 To Treat Crigler-Najjar Syndrome 2/1/2017 7:33:02 AM
Audentes (BOLD) Provides Full Year 2017 Strategic Outlook And Financial Guidance 1/9/2017 10:50:48 AM
Audentes (BOLD) Appoints Julie Anne Smith To Board Of Directors 12/13/2016 7:17:40 AM
Audentes (BOLD) Announces Initiation Of Large-Scale cGMP Production At Its Gene Therapy Manufacturing Facility 11/29/2016 9:10:35 AM
Audentes (BOLD) Reports Third Quarter 2016 Financial Results And Provides Corporate Update 11/11/2016 2:07:00 PM
Audentes (BOLD) To Present At Upcoming Investor Conferences 9/21/2016 8:18:43 AM
Audentes (BOLD) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 9/1/2016 12:01:26 PM
Audentes (BOLD) Announces First Patient Enrolled In The INCEPTUS Clinical Assessment Study Of XLMTM 8/17/2016 6:50:25 AM